



GLOBAL TASK FORCE ON
CHOLERA CONTROL

**UPDATE (JUNE 2018 - CURRENT)
ORAL CHOLERA VACCINE (OCV) WORKING
GROUP**

Kashmira Date
OCV Working Group, GTFCC

GTGCC Annual Meeting, 3 June 2019



OCV RELATED RECOMMENDATIONS AND PROPOSED WORKPLAN (GTFCC ANNUAL MEETING 2018)

- ✓ Country support: agreement that OCV requests should be part of a cholera control plan, need for a revised process including OCV
- ✓ Technical guidance to support development of cholera control plans, including OCV use
- ✓ “OCV-WASH Integration/Linkages”: technical note on what WASH measures should be implemented with OCV campaigns
- ✓ Research agenda: Wellcome Trust-DFID support
- ✓ GAVI 2019 support and vaccine investment strategy


OVERVIEW OF OCV USE 2014 – 2019 (AS OF MAY 2019)

Year	Doses shipped	Doses requested
2013	204,500	204,500
2014	1,486,215	1,962,485
2015	2,502,775	4,419,127
2016	4,645,345	5,021,672
2017	9,979,595	21,800,653
2018	17,447,580	100,781,390
Total	36,266,010	134,189,827

2019 (As of 31 May)

14,486,070 doses have been requested

10,099,639 have been shipped



MAJOR DEVELOPMENTS/UPDATES (JULY 2018 – MAY 2019)

- ✓ Framework for the development of National Cholera Plans (NCPs), including OCVs and related M & E
- ✓ Draft technical guidance note on integration of WASH and community engagement activities with OCV campaigns (collaboration with the WASH WG)
- ✓ Prioritization of a research agenda (July 2018) and call for proposals (Oct – Nov 2018) by Wellcome Trust-DFID
- ✓ Defining GAVI 2019-2020 support and vaccine investment strategy
- ✓ OCV WG meeting (Dec 2018): key updates and recommendations

GTFCC RESEARCH AGENDA MEETING (WELLCOME/DFID), JULY 2018

PRE-IMPLEMENTATION	IMPLEMENTATION	POST IMPLEMENTATION / M&E
<p>Burden of disease and identification of hotspots:</p> <ul style="list-style-type: none"> Description of existing hotspots to inform the definition of hotspots: <ul style="list-style-type: none"> Quantification: laboratory confirmation, sero-surveys Characterization: changing incidence and timing, WASH conditions, transmission (in and out) Accessible laboratory confirmation methods in hotspots Develop and pilot an assessment tool – hotspot vs at risk (using a tier approach), including lab capacity Improve estimates of mortality and where it occurs <p>Transmission dynamics:</p> <ul style="list-style-type: none"> Macro level analysis: laboratory data, Whole Genome Sequencing, epidemiological data Community/household level: environmental reservoir vs human to human transmission, Social science Disease modelling for outbreak short term prediction 	<p>Optimization of interventions at the community level:</p> <ul style="list-style-type: none"> Rapid Diagnostic Tests Use of antibiotic (targeted prophylaxis) WASH package (short medium and long term) Delivery strategies for OCV including new cholera vaccines, use in “controlled temperature chain” (CTC) Behavior change <p>Operational research on cholera vaccine:</p> <ul style="list-style-type: none"> co-administration with other vaccines, vaccine duration of protection, simplification of delivery <p>Synergies of interventions: OCV and WASH</p> <p>Cholera And Severe Acute Malnutrition (SAM)</p>	<p>Effectiveness:</p> <ul style="list-style-type: none"> Outcomes and process for continuous improvement Improve targeting and use of interventions in country <p>Change in attitude:</p> <ul style="list-style-type: none"> Political will Lessons learnt to be documented
<p>CROSS-CUTTING</p>		
<p>Social sciences</p> <ul style="list-style-type: none"> Country engagement: policy drivers, determinants and barriers Documenting success stories through case studies – to be linked to advocacy efforts <p>Impact:</p> <ul style="list-style-type: none"> Level of WASH coverage needed to stop transmission, Role of disease estimate modelling to support countries in defining control plans Impact of outbreak response (including OCV reactive campaigns) and endemic cholera control activities <p>Cost effectiveness/value for money</p>		


GAVI VACCINE INVESTMENT STRATEGY

Continue to support OCV through preventive immunization (hotspots) - Gavi Executive Board Final Decision in June 2019

Bridge funding for continued use of the OCV stockpile for endemic settings in 2020, and approved 2019–2020 funding for activities related to the cholera learning agenda

Additional considerations

- Continued support will be contingent on sufficient replenishment of Gavi's funds
- Support will be given to GTFCC-validated national cholera plans (NCPs)
- Reviews by Gavi's Independent Review Committees
- Co-financing



Experts consulted in Phase 2 of VIS


Experts consulted

Abdinasir Abubakar - WHO EMRO	Justin Lesser – JHU
Andrew Azman - JHU	Myron M. “Mike” Levine – U of MD
Hans Christiansen - UNICEF	Tina Lorenson – BMGF
Kashmira Date - CDC	Imran Mirza – UNICEF
Johanna Fihman – WHO HQ	Vittal Mogasale - IVI
Guillermo Gimeno – UNICEF	Francisco Luquero – Epicentre
Tracey Goodman – WHO HQ	Julia Lynch – IVI
Linda Omar Haj – WHO AFRO	Helen Matzger – WHO HQ
Alan Hinman – independent	Lorenzo Pezzoli – WHO HQ
Shannon Larsen - BMGF	David Sack – JHU
Dominique Legros – WHO HQ	

KEY UPDATES AND RECOMMENDATIONS

OCV-WG MEETING (DECEMBER 2018)

WHO Approved Package Insert Updates




SANOFI PASTEUR

2


SHANTHA
A SANOFI COMPANY

EuBiologics has supplied more than 22M doses of Euvichol and Euvichol-Plus to cholera endemic/outbreak countries through UNICEF since 2016


of doses supplied (Euvichol vs Euvichol-Plus)



No. of doses supplied yearly



Doses shipped by country (N=10)



KEY UPDATES AND RECOMMENDATIONS OCV-WG MEETING (DECEMBER 2018)

- ✓ Continue working with Gavi to help frame Gavi's coming OCV investment and its linkage with the ending cholera roadmap
- ✓ Facilitate close involvement of immunization programs (Expanded Program on Immunization [EPI] and Global Polio Eradication Initiative[GPEI])
- ✓ Establish a small group to further develop guidance on OCV-WASH integration and linkages with longer-term WASH

NEXT STEPS

- ✓ Continue close engagement with Gavi
- ✓ Provide country support for OCV planning, implementation, monitoring and evaluation through the GTFCC platform and the roadmap framework
- ✓ Continue collaboration with other GTFCC working groups
 - Surveillance WG: targeting for hotspots, impact assessments
 - WASH WG: OCV-WASH integration/linkages
- ✓ Build adequate monitoring, evaluation and ongoing research plans (research agenda priorities)
- ✓ Engage additional manufacturers on new vaccine formulations

Thank you

Together we can
#endcholera



GLOBAL TASK FORCE ON
CHOLERA CONTROL

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.